Findings showed that the investigational combination was well tolerated in select virologically suppressed HIV patients. Credit: National Cancer Institute on Unsplash.

Gilead Sciences has reported positive data from the Phase Ib clinical trial of lenacapavir, along with broadly neutralising antibodies (bNAbs) teropavimab and zinlirvimab, to treat HIV.

The trial was designed for assessing the efficacy and safety of the investigational combination regimen of lenacapavir with teropavimab and zinlirvimab as a potential twice-yearly approach in selected adult HIV patients, who were virologically suppressed for more than two years while taking antiretroviral therapy (ART).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In the trial, the participants were sensitive to both bNAbs by HIV proviral DNA phenotype and at study entry they had a ≥500 CD4 cell count.

Findings showed that the investigational combination was well tolerated and had high efficacy in select virologically suppressed HIV patients.

In the study, 90% of the participants who were receiving the complete study regimen maintained virologic suppression at week 26.

See Also:

No serious adverse events (AEs) or AEs that led to study drug discontinuation were overserved in the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Gilead Sciences HIV Clinical Development vice-president Jared Baeten said: “We’re excited to share these promising results that reinforce lenacapavir’s potential to be a foundational agent for long-acting combination HIV treatment options, and we are especially pleased to see the potential of the combination of lenacapavir plus bNAbs dosed once every six months.

“We are committed to exploring novel therapy approaches that may help deliver care for all people living with HIV, with a focus on developing person-centric options that fit into the diverse lives of people living with the virus, as we continue in our pursuit of ending the HIV epidemic for everyone, everywhere.”

The company stated that the data from the Phase Ib clinical trial will be used in further evaluating the investigational combination in a Phase II trial as a long-acting HIV treatment option.